End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
28.78 CNY | +0.81% | +2.20% | -6.98% |
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 63% by 2026.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 34.88 times its estimated earnings per share for the ongoing year.
- The company appears highly valued given the size of its balance sheet.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.98% | 6.55B | C | ||
-4.66% | 87.53B | A- | ||
+2.63% | 40.42B | A- | ||
-20.34% | 29.48B | B- | ||
+57.16% | 25.43B | A | ||
-17.87% | 11.49B | B- | ||
-44.02% | 11.3B | B | ||
-15.61% | 11.1B | D+ | ||
+4.27% | 8.75B | B+ | ||
-8.42% | 7.99B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 600161 Stock
- Ratings Beijing Tiantan Biological Products Co., Ltd.